70 completed, 14 terminated, 14 withdrawn, 6 recruiting. 113 Phase 2, 26 Phase 1, 14 Phase 3.
Follow Hypoglycemia: new trials by email Literature Review of Hypoglycemia trials Research Report on Hypoglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes Allogeneic pancreatic endocrine cell clusters - Diabete Mellitus, Diabete Type 1 | Phase 1 / Phase 2 | Not yet recruiting | Seraxis | 9 | 2026-11-01 | 2026-10-19 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes PAL-119, Placebo - Healthy Volunteers and Diabetes Participants | Phase 1 / Phase 2 | Not yet recruiting | Paulex Bio Inc. | 147 | 2026-11-01 | 2026-10-28 |
| Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease Anakinra (interleukin-1 receptor antagonist), Placebo Comparator (0.9% NaCl) - Postprandial Hypoglycemia, End-stage Renal Disease (ESRD) | Phase 2 | Not yet recruiting | Marc Donath | 1 | 2026-07-01 | 2026-05-12 |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus CX11, Placebo - Type II Diabetes Mellitus | Phase 2 | Recruiting | Corxel Pharmaceuticals | 240 | 2026-02-06 | 2026-09-15 |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin LY3938577, Degludec - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Eli Lilly and Company | 100 | 2025-10-13 | 2026-07-13 |
| A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes Allogeneic Human E-islet (E-islet 01) - Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness | Phase 1 / Phase 2 | Recruiting | EndoCell Therapeutics, Inc. | 21 | 2025-08-11 | 2025-08-22 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus OPF-310 - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Recruiting | Otsuka Pharmaceutical Factory, Inc. | 13 | 2025-06-10 | 2026-08-21 |
| A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia Allogeneic Pancreatic Endocrine Cell Clusters - Diabetes Mellitus Type 1 | Phase 1 / Phase 2 | Withdrawn | Seraxis | 2025-04-01 | 2025-10-16 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) Glibenclamide, Pharmacokinetics study, C-peptide proinsulin ratio - Transient; Hypoglycemia, Neonatal, Preterm | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 35 | 2023-05-20 | 2026-10-02 |
| Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride) - Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 2 | Completed | Melbourne Health | 68 | 2023-02-13 | 2025-12-24 |
| Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults Dasiglucagon, Placebo - Hypoglycemia, Glucose Metabolism Disorders | Phase 2 | Withdrawn | Zealand Pharma | 2023-02-01 | 2023-02-21 | |
| Vitamin E Efficacy in HI/HA Vitamin E - Hyperinsulinism-Hyperammonemia Syndrome | Phase 2 | Withdrawn | Children's Hospital of Philadelphia | 2022-11-01 | 2022-12-13 | |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes empagliflozin, anakinra, saline subcutaneous (s.c.) (placebo) - Postprandial Hypoglycemia | Phase 2 | Withdrawn | University Hospital, Basel, Switzerland | 2022-06-24 | 2026-02-20 | |
| Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis Insulin Glargine - DKA | Phase 2 | Terminated | HealthPartners Institute | 8 | 2022-05-31 | 2024-06-18 |
| HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) HM15136 - Congenital Hyperinsulinism | Phase 2 | Active not recruiting | Hanmi Pharmaceutical Company Limited | 17 | 2022-05-05 | 2026-08-26 |
| Treatment of Post-bariatric Hypoglycaemia Dasiglucagon, HyoPen, Placebo - Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia | Phase 2 | Completed | Filip Krag Knop | 24 | 2021-08-20 | 2023-02-02 |
| Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes Dasiglucagon - Type 1 Diabetes, Hypoglycemia | Phase 2 | Completed | Steno Diabetes Center Copenhagen | 24 | 2021-04-27 | 2022-09-07 |
| Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation AT-1501 - Type 1 Diabetes Mellitus | Phase 2 | Withdrawn | Anelixis Therapeutics, LLC | 2021-02-19 | 2022-08-10 |
Showing 20 of 113. Sign in to see all of them.
Diabetes Mellitus, Type 1 (59) · Diabetes Mellitus (20) · Insulin Resistance (20) · Congenital Hyperinsulinism (16) · Hyperinsulinism (9) · Glucose Metabolism Disorders (8) · Hyperglycemia (8) · Diabetes Complications (7) · Diabetes Mellitus, Type 2 (7) · Metabolic Diseases (6) · Autoimmune Diseases (4) · Motor Activity (4) · Endocrine System Diseases (3) · Immune System Diseases (3)
Nutritional and Metabolic Diseases (113) · Metabolic Diseases (107) · Glucose Metabolism Disorders (105) · Endocrine System Diseases (79) · Diabetes Mellitus (59) · Immune System Diseases (57) · Autoimmune Diseases (55) · Hyperinsulinism (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Digestive System Diseases (17) · Infant, Newborn, Diseases (15) · Pancreatic Diseases (15) · Pathological Conditions, Signs and Symptoms (6) · Female Urogenital Diseases and Pregnancy Complications (5)
Glucagon (16) · Insulin (14) · Insulin Aspart (9) · Methods (8) · dasiglucagon (6) · Antilymphocyte Serum (5) · Insulin, Regular, Human (5) · Exenatide (4) · Exercise (4) · Insulin Infusion Systems (4) · Saline Solution (4) · Sirolimus (4) · Sodium Chloride (4) · fluorodopa F 18 (4) · Continuous Glucose Monitoring (3)
Institut de Recherches Cliniques de Montreal (17) · University of Minnesota (8) · Xeris Pharmaceuticals (8) · Florida Atlantic University (7) · Jaeb Center for Health Research (4) · Children's Hospital of Philadelphia (3) · Diva De Leon (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Zealand Pharma (3) · Assistance Publique - Hôpitaux de Paris (2) · City of Hope Medical Center (2) · Eli Lilly and Company (2) · Montefiore Medical Center (2) · Radboud University Medical Center (2) · Rodolfo Alejandro (2)
United States (64) · Canada (25) · Denmark (6) · United Kingdom (6) · France (4) · Germany (4) · Israel (4) · Switzerland (3) · Netherlands (2) · Argentina (1) · Australia (1) · Belgium (1) · Bulgaria (1) · China (1) · Georgia (1)
Bernhard J. Hering, M.D. (5) · Betty Tuller, Ph.D (3) · Betty Tuller, PhD (3) · John Lum, MS (3) · Allan Gordon, MD, PhD (2) · Bruce A Buckingham, MD (2) · Christian Laugesen, MD (2) · Fouad Kandeel, MD, PhD (2) · Jeff Bornstein, MD (2) · Lisa J States, MD (2) · Remi Rabasa-Lhoret (2) · Roy W Beck, MD, PhD (2) · A.M. James Shapiro, MD, PhD (1)
PMID 39780302, PMID 14961992, PMID 15713772, PMID 17236890, PMID 17895314, PMID 20332358, PMID 22522612, PMID 22855730, PMID 22996144, PMID 23414871, PMID 23438305, PMID 23883408, PMID 24023652, PMID 24314195, PMID 24314196, PMID 24804697, PMID 25263215, PMID 25387217, PMID 25393157, PMID 25434967, PMID 25761202, PMID 26049549, PMID 26066705, PMID 26068866, PMID 26072052, PMID 26345338, PMID 26523526, PMID 26861921, PMID 27704167, PMID 28860128, PMID 28941330, PMID 29273578, PMID 29355439, PMID 29393675, PMID 29506054, PMID 29605395, PMID 29776987, PMID 31615852, PMID 32740723, PMID 33050728, PMID 34282646, PMID 35320361, PMID 35416981, PMID 35475907, PMID 36689626, PMID 37037948, PMID 40107271
R01DK085591 (3), 2017 (2), 2008 (1), 2019 (1), 2025 (1), R01DK062440 (1), R01DK079974 (1), R03DK078535 (1), R44DK085809 (1), R44DK096706 (1), R44DK096715 (1), R44DK105691 (1), R44DK107114 (1)